Biomedical Engineering Reference
In-Depth Information
[5] Scherzer R. Quality by Design: A Challenge to the Pharma Industry. Board FS, 2002.
[6] Hussain AS. Quality by Design: Next Steps to Realize Opportunities. Presented to the Food
and Drugs Administration Advisory Committee for Pharmaceutical Science: Manufacturing
Science Subcommittee, 2003.
[7] Woodcock J. Pharmaceutical quality in the 21st century—an integrated systems approach.
Workshop on Pharmaceutical Quality Assessment—A Science and Risk-Based CMC
Approach in the 21st Century, North Bethesda, MD, AAPS, 2005.
[8] U.S. FDA. Submission of chemistry, manufacturing, and controls information in a new drug
application under the new pharmaceutical quality assessment system: notice of pilot
program. HHS, Federal Register 2005;70:40719-40720.
[9] BIO. Biotechnology Industry Facts, 2008. http://bio.org/speeches/pubs/er/statistics.asp.
[10] Rathore AS, Branning R, Cecchini D. Quality: design space for biotech products. BioPharm
Int 2007;20(4):36-40.
[11] ICH. Q8(R1) Pharmaceutical Development Revision 1, 2008. (step 4, 11/13/2008, http://
www.ich.org/cache/compo/363-272-1.html#Q8).
[12] Nasr M. Risk-based CMC review and quality assessment: What is quality by design (QbD)?
2006 FDA/Industry Conference, School of Pharmacy—Temple University, 2006.
[13] Woodcock J. The concept of pharmaceutical quality. Am Pharm Rev 2004;7:1-3.
[14] Morrow JD. Pancreatic enzyme replacement therapy. Am J Med Sci 1989;298:357-359.
[15] Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in
cystic fibrosis. Pediatr Pulmonol 2006;41:35-49.
[16] Jani R, Triplitt C, Reasner C, Defronzo RA. First approved inhaled insulin therapy for
diabetes mellitus. Expert Opin Drug Deliv 2007;4:63-76.
[17] Vaczek D. Promoting dosing accuracy with pre-filled syringes. PharmMed Pack News 2007;
s42-s50.
[18] Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Epoetin-associated pure
red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial
Transplant 2005;20(Suppl. 3):iii33-iii40.
[19] RyanMH, Heavner GA, Brigham-BurkeM, McMahon F, ShanahanMF, Gunturi SR, Sharma
B, Farrell FX. An in vivo model to assess factors that may stimulate the generation of an
immune reaction to erythropoietin. Int Immunopharmacol 2006;6:647-655.
[20] Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat
Biotechnol 2006;24:613-614.
[21] Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia “epidemic”—mystery complete-
ly revealed? Perit Dial Int 2007;27(Suppl. 2):S303-S307.
[22] ICH. Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/
Biological Products, 1999. http://www.fda.gov/cder/guidance/Q6Bfnl.PDF.
[23] Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol
2003;112:15-21.
[24] Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on
the immunogenicity of biologics. Trends Biotechnol 2006;24:274-280.
[25] Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of
antibody immune responses against biological drugs. Nat Biotechnol 2007;25:555-561.
[26] Kozlowski S, Swann P. Current and future issues in the manufacturing and development of
monoclonal antibodies. Adv Drug Deliv Rev 2006;58:707-722.
